13 completed. 13 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 13 |
| Phase 2 | 5 | Completed 5 |
Follow Telangiectasis: new trials by email Literature Review of Telangiectasis trials Research Report on Telangiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Elimusertib (BAY1895344), Pembrolizumab (Keytruda®) - Advanced Solid Tumors | Phase 1 | Completed | Bayer | 56 | 2019-09-30 | 2024-04-02 |
| MRA With Feraheme in HHT Feraheme MRI/MRA - Hereditary Hemorrhagic Telangiectasia | Phase 1 | Completed | University of California, Los Angeles | 10 | 2016-11-01 | 2019-01-25 |
| Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study Pomalidomide - Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia | Phase 1 | Completed | The Cleveland Clinic | 9 | 2015-01-27 | 2020-07-15 |
| Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose bevacuzimab spray - Telangiectasia, Hereditary Hemorrhagic | Phase 1 / Phase 2 | Completed | University Hospital, Caen | 20 | 2014-12-15 | 2026-07-30 |
| Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept Topical timolol maleate, placebo saline drops - Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Completed | Unity Health Toronto | 5 | 2013-05-01 | 2023-09-21 |
| The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia Bevacizumab - Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic | Phase 1 | Completed | Hospices Civils de Lyon | 42 | 2011-10-01 | 2021-10-19 |
| Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia Sclerotherapy, Standard Treatment - Epistaxis, Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Completed | University of Minnesota | 18 | 2011-02-01 | 2019-11-01 |
| Combination Therapy for the Treatment of Rosacea calcium dobesilate, pulsed dye laser - Erythematotelangiectatic Rosacea | Phase 1 | Completed | Ellen Marmur | 6 | 2009-07-01 | 2019-06-17 |
| Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy ranibizumab injection (0.5 mg) - Coats' Disease, Idiopathic Retinal Telangiectasia | Phase 1 / Phase 2 | Completed | Manhattan Eye, Ear & Throat Hospital | 18 | 2007-05-01 | 2012-10-25 |
| Effects of PRK 124 Lotion in Acne Rosacea PRK 124 - Acne Rosacea | Phase 1 / Phase 2 | Completed | University of California, Irvine | 24 | 2007-04-01 | 2014-01-17 |
| Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation Ranibizumab - Telangiectasia | Phase 1 | Completed | National Eye Institute (NEI) | 5 | 2007-03-27 | 2017-07-02 |
| Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation Ranibizumab - Telangiectasia | Phase 1 | Completed | National Eye Institute (NEI) | 5 | 2007-03-27 | 2017-07-02 |
| Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial Ranibizumab - Telangiectasia | Phase 1 | Completed | Johns Hopkins University | 10 | 2006-09-01 | 2012-11-14 |
Telangiectasia, Hereditary Hemorrhagic (6) · Epistaxis (2) · Idiopathic Juxtafoveal Retinal Telangiectasia (2) · Papilledema (2) · Rosacea (2) · Acne Vulgaris (1) · Ataxia Telangiectasia (1) · Erythema (1) · Flushing (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Myopia, Degenerative (1) · Polypoidal Choroidal Vasculopathy (1) · Pseudoxanthoma Elasticum (1) · Retinal Telangiectasis (1)
Cardiovascular Diseases (13) · Vascular Diseases (13) · Congenital Abnormalities (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Hemorrhagic Disorders (7) · Hemostatic Disorders (7) · Cardiovascular Abnormalities (6) · Vascular Malformations (5) · Nervous System Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Eye Diseases (3) · Pathologic Processes (3)
Ranibizumab (4) · BAY 1895344 (1) · Bevacizumab (1) · Calcium Dobesilate (1) · Ferrosoferric Oxide (1) · Lasers, Dye (1) · Sclerotherapy (1) · Sodium Tetradecyl Sulfate (1) · Timolol (1) · pembrolizumab (1) · pomalidomide (1) · pyratine 6 (1)
National Eye Institute (NEI) (2) · Bayer (1) · Ellen Marmur (1) · Hospices Civils de Lyon (1) · Johns Hopkins University (1) · Manhattan Eye, Ear & Throat Hospital (1) · The Cleveland Clinic (1) · Unity Health Toronto (1) · University Hospital, Caen (1) · University of California, Irvine (1) · University of California, Los Angeles (1) · University of Minnesota (1)
United States (10) · Canada (1) · France (1) · Germany (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Ellen Marmur, MD (1) · Gerald D Weinstein, MD (1) · Holly Boyer, MD (1) · Justin McWilliams, MD (1) · Keith McCrae, MD (1) · Lawrence A. Yannuzzi, MD (1) · Marie E Faughnan, MD MSc FRCPC (1) · Neil M. Bressler, MD (1)
2018 (1), U54NS065705 (1)